Search results
Results From The WOW.Com Content Network
Biotechnology in India is a sunrise sector within the Indian economy. [1] Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. [2]
National Stock Exchange of India; Type: Stock exchange: Location: Mumbai, Maharashtra, India: Founded: 27th November 1992: Owner: Various group of domestic and global financial institutions, public and privately owned entities and individuals [1] Key people: Ashishkumar Chauhan (MD & CEO) Currency: Indian rupee (₹) No. of listings: 2,671 (Dec ...
India's revenue from pharmaceutical exports was $25.3 billion in the 2022-2023 financial year. [7] In terms of the global market, India currently holds an accountable share and is known as the pharmacy of the world. [9] The country is the largest global supplier of generic medicine. [10] India produces more than 50% the world's vaccines. [11]
This is a list of tables showing the historical timeline of the exchange rate for the Indian rupee (INR) against the special drawing rights unit (SDR), United States dollar (USD), pound sterling (GBP), Deutsche mark (DM), euro (EUR) and Japanese yen (JPY). The rupee was worth one shilling and sixpence in sterling in 1947.
Based on the company's share price of around $10 as of August 27, the average Wall Street analyst price target signals an upside of over 100%. So, what does Artiva do, and why is Wall Street so ...
State Bank of India (SBI) Banking 5.18 10 Bajaj Finance Financial Services 4.46 2021. Top 10 companies in India in 2021 by market capitalization: [17] [15] [16]
During the COVID-19 pandemic, the company signed a pact with Baylor College of Medicine, Texas Children's Hospital and Dynavax Technologies to develop a COVID-19 vaccine. [6] [7] The vaccine Corbevax [8] /Bio E COVID-19 was expected to roll out in 2021 with 75 to 80 million doses manufactured per month; the production was expected to reach 1 billion doses by the end of 2022 under the Quad ...
The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed.They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". [8]